Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study

Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study

Purpose: To compare testosterone castration levels between patients treated with the gonadotropin-releasing hormone (GnRH) antagonist, degarelix, and GnRH agonist. Materials and Methods: Patients with prostate cancer (PCa) of a single outpatient clinic were randomized (2:1) to receive degarelix (gr...

Full description

Bibliographic Details
Main Authors: Vaios-Konstantinos Mytilekas, Efstathios Papaefstathiou, Periklis Koukourikis, Xenofon Ouzounidis, Stavros Kazantzidis, Konstantinos Hatzimouratidis
Format: Article
Language:English
Published: Korean Urological Association 2023-11-01
Series:Investigative and Clinical Urology
Subjects:
androgen deprivation therapy
prostate cancer
testosterone
Online Access:https://www.icurology.org/pdf/10.4111/icu.20230027

Internet

https://www.icurology.org/pdf/10.4111/icu.20230027

Similar Items